Evidence map›Paper›PMID 36344940›Full record

ArticleBMC pulmonary medicine2022

The effect of N-acetylcysteine in patients with non-cystic fibrosis bronchiectasis (NINCFB): study protocol for a multicentre, double-blind, randomised, placebo-controlled trial.

Yue Liao, Yanqiu Wu, Kai Zi, Yongchun Shen, Tao Wang, Jiangyue Qin, Lei Chen, Mei Chen, Lin Liu, Weiming Li and 4 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Exacerbations of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  3. Exacerbation Prevention and Management of Bronchiectasis.Tuberculosis and respiratory diseases · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Yue Liao *Division of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Yanqiu Wu *Division of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Kai ZiDivision of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Yongchun ShenDivision of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Tao WangDivision of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Jiangyue QinDivision of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Lei ChenDivision of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Mei ChenDepartment of Respiratory, Chengdu Fifth People's Hospital, Chengdu, China.
Lin LiuDepartment of Respiratory and Critical Care Medicine, 363 Hospital, Chengdu, China.
Weiming LiDepartment of Respiratory Medicine, Chengdu Sixth People's Hospital, Chengdu, China.
Hui ZhouDepartment of Respiratory, Chengdu University Affiliated Hospital, Chengdu, China.
Shuguan XiongDepartment of Clinical Laboratory, Nuclear Industry 416 Hospital, the 2nd Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Fuqiang WenDivision of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China. wenfuqiang@scu.edu.cn.ORCID http://orcid.org/0000-0001-6205-4758
Jun ChenDivision of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China. junchen@scu.edu.cn.
Sichuan University · CNChengdu Fifth People's Hospital · CNChengdu Medical College · CNChengdu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundN-acetylcysteine (NAC), which is specifically involved in airway mucus clearance and antioxidation, is recommended by the treatment guideline for non-cystic fibrosis bronchiectasis (NCFB). However, there is little clinical evidence of its long-term efficacy concerning quality of life (QoL) and exacerbation in patients with NCFB. In addition, the influences of NAC on airway bacterial colonization, chronic inflammation and oxidative stress in NCFB are also unclear.

methodsNINCFB is a prospective, multicentre, double-blind, randomised, placebo-controlled trial that will recruit 119 patients with NCFB and randomly divide them into an NAC group (n = 79) and a control group (n = 40). Participants in the NAC group will receive 600 mg oral NAC twice daily for 52 weeks, while patients in the control group will receive 600 mg placebo twice daily for 52 weeks. The information at baseline will be collected once participants are enrolled. The primary endpoints are the changes in St George's Respiratory Questionnaire scores and the number of exacerbations in 52 weeks. The secondary endpoints are the 16S rRNA of sputum and the levels of inflammatory factors and oxidative stressors in sputum and serum. Other data related to radiography, lung function tests, number of oral and/or intravenous antibiotic therapies and adverse events (AEs) will also be analysed. Further subgroup analysis distinguished by the severity of disease, severity of lung function, airway bacterial colonization and exacerbation frequency will be performed. DISCUSSION: The objective of this study is to determine the long-term efficacy of NAC on QoL and exacerbation of NCFB and to explore the effectiveness of NAC for antibiosis, anti-inflammation and antioxidation in NCFB. The study results will provide high-quality clinical proof for the revision and optimization of treatment guidelines and for expert consensus on NCFB treatment.

trial registrationThe trial was registered on the Chinese Clinical Trial Register at April 11, 2020 ( chictr.org.cn , ChiCTR2000031817).

Indexed as

BronchiectasisCystic FibrosisAcetylcysteineAnti-Bacterial AgentsDouble-Blind MethodFibrosisHumansMulticenter Studies as TopicProspective StudiesQuality of LifeRandomized Controlled Trials as TopicRNA, Ribosomal, 16SAcetylcysteineAnti-Bacterial AgentsRNA, Ribosomal, 16SBacterial colonizationChronic inflammationClinical trialExacerbationN-acetylcysteineNon-cystic fibrosis bronchiectasisOxidative stressQuality of life

Identifiers

PMID36344940
PMCPMC9639270
OpenAlexW4308440456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.